retatrutide mechanism retatrutide clinical trials 2024 2025 More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Retatrutide: Phase 3 Results (Up

This receptor selectivity profile is the key pharmacological distinction between the two analogues, and makes MT-1 the reference compound in studies focused specifically on the MC1R/pigmentation axis without the confounding MC3R (energy homeostasis) and MC4R (appetite, sexual function) activity associated with MT-2

Generative AI statement The authors declare that Gen AI was used in the creation of this manuscript

Yang JC, Liu M, Huang RH, Zhao L, Niu QJ, Xu ZJ, et al

Staying well hydrated helps the appetite-suppressing effects of retatrutide work optimally and prevents false hunger signals from being confused with thirst